ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2228 • 2014 ACR/ARHP Annual Meeting

    Has MRI an Added Value over Serum Creatine Kinase Measurement in Myositis?

    Nicolo Pipitone1, Antonella Notarnicola2, Giulio Zuccoli3, Lucia Spaggiari4, Gabriele Levrini5, Arnaldo Scardapane6, Florenzo Iannone2, Giovanni Lapadula2 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 3Children's Hospital of Pittsburgh, Pittsburgh, PA, 4Radiology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 5Arcispedale S Maria Nuova, Reggio Emilia, Italy, 6Radiology, University of Bari, Bari, Italy

    Background/Purpose MRI is widely used to assess inflammation in myositis. Muscle edema on short tau inversion recovery (STIR) sequences is thought to reflect active inflammation.…
  • Abstract Number: 2229 • 2014 ACR/ARHP Annual Meeting

    How Often Are Clinically Amyopathic Dermatomyositis Patients Truly Amyopathic?

    Edward J. Oberle1,2, Michelle Bayer3,4, Dominic O. Co4,5 and Yvonne Chiu4,5, 1Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 2Rheumatology, Children's Hospital of Wisconsin, Milwaukee, WI, 3Dermatology, Medical College of Wisconsin, Milwaukee, WI, 4Children's Hospital of Wisconsin, Milwaukee, WI, 5Pediatrics, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder primarily involving the skin and striated muscle.  Classic JDM presents with rash, proximal muscle weakness, and…
  • Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting

    Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials

    Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Jeppe Andersen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

    Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
  • Abstract Number: 2191 • 2014 ACR/ARHP Annual Meeting

    Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease

    Ross Thibodaux1, Bahnsen Miller1 and Stephen Lindsey2,3, 1Internal Medicine, Louisiana State University Health Science Center, Baton Rouge, LA, 2Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, 3Internal Medicine - Rheumatology, Louisiana State University Health Science Center, Baton Rouge, LA

    Background/Purpose: Calcinosis, or dystrophic calcification, is a poorly understood, debilitating condition commonly manifested in connective tissue diseases such as scleroderma and polymyositis. Despite treatment of…
  • Abstract Number: 2192 • 2014 ACR/ARHP Annual Meeting

    Successful Therapy with Intravenous Sodium Thiosulfate for Adult Dermatomyositis Associated Calcinosis

    Maria Constanza Florestano1,2 and Mauricio Álamo3, 1University of Valparaiso, Chile, Santiago de Chile, Chile, 2Internal Medicine, Military Hospital, Santiago of Chile, Santiago de Chile, Chile, 3Rheumatology, Clinica Dávila, Santiago of Chile, Santiago of Chile, Chile

    Background/Purpose: Calcinosis cutis is the deposition of insoluble calcium salts in skin or subcutaneous tissue. In cases related to CTD, presents with normal calcium/phosphorus metabolism,…
  • Abstract Number: 2193 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Raynaud’s Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry’s Disease: A Cross-Sectional Study

    Samuel Deshayes1, Roland Jaussaud2, Bernard Imbert3, Olivier Lidove4, Jean-Jacques Parienti5, Nathalie Triclin6, Laurent Auboire7 and Boris Bienvenu1, 1Médecine interne, CHU Côte de Nacre, CAEN, France, 2Médecine interne, maladies infectieuses, immunologie clinique, CHU de Reims, REIMS, France, 3CHU, Grenoble, Grenoble, France, 4Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 5Biostatistiques, CHU Côte de Nacre, CAEN, France, 6Association des Patients de la Maladie de Fabry, VENDRESSE, France, 7Inserm U930, UMR Imagerie et Cerveau, TOURS, France

    Background/Purpose: Fabry's disease (FD) is a lysosomal disorder leading to progressive systemic involvement, including neurologic and vascular. We hypothesize that the microangiopathy observed in FD…
  • Abstract Number: 2194 • 2014 ACR/ARHP Annual Meeting

    Blue Digit Syndrome: The Rheumatologist’s Perspective

    Helena Borrell1, Javier Narváez2, Eulalia Armengol1, Milagros Ricse1, Gloria Albert1, Sergi Heredia1, Andrea Zacarias1, Carmen Gomez Vaquero1 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain

    Background/Purpose: Blue or purple digit syndrome (or sign) is a cutaneous manifestation of multiple diseases that produce acute or subacute ischemic compromise in one or…
  • Abstract Number: 2195 • 2014 ACR/ARHP Annual Meeting

    Eculizumab Treatment of Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): World Experience to Date

    Aixa Toledo-Garcia1, Lee S. Shapiro2,3 and Jessica F. Farrell2,3,4, 1Rheumatology, The Center for Rheumatology, Albany, NY, 2Steffens Scleroderma Center, Saratoga Springs, NY, 3The Center for Rheumatology, Albany, NY, 4Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY

    Background/Purpose Malignant atrophic papulosis (MAP) is an obliterative vasculopathy which presents with distinctive cutaneous lesions but can progress over months to years to systemic disease…
  • Abstract Number: 2196 • 2014 ACR/ARHP Annual Meeting

    Treprostinil Use in Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): Review of Worldwide Experience to Date

    Lee S. Shapiro1,2, Aixa Toledo-Garcia1,3 and Jessica F. Farrell1,4,5, 1Steffens Scleroderma Center, Saratoga Springs, NY, 2Albany Medical College, Albany, NY, 3Rheumatology, The Center for Rheumatology, Albany, NY, 4Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, 5The Center for Rheumatology, Albany, NY

    Background/Purpose Malignant atrophic papulosis (MAP) is a rare thrombo-occlusive vasculopathy that presents with cutaneous only lesions but can progress after months or years to rapidly fatal systemic…
  • Abstract Number: 2197 • 2014 ACR/ARHP Annual Meeting

    Malignant Atrophic Papulosis (MAP) Complicating Connective Tissue Diseases (CTDs)

    Aixa Toledo-Garcia1,2, Lee S. Shapiro2,3,4 and Jessica F. Farrell2,3,5, 1Rheumatology, The Center for Rheumatology, Albany, NY, 2Steffens Scleroderma Center, Saratoga Springs, NY, 3The Center for Rheumatology, Albany, NY, 4Albany Medical College, Albany, NY, 5Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY

    Background/Purpose Malignant Atrophic Papulosis (MAP) is a rare vasculopathy of unknown etiology commonly presenting with cutaneous lesions, but can progress to multisystem disease with a…
  • Abstract Number: 2198 • 2014 ACR/ARHP Annual Meeting

    The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing?

    Zsolt Kulcsar1, Clinton Morgan2, Peter Kaufman3, Jonathan Jones4 and William Rigby5, 1Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, 2Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH, 3Hematology/Oncology, Dartmouth Hitchcock Medical Center, lebanon, NH, 4Rheumatology Clinic, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 5Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH

    Background/Purpose: Aromatase Inhibitor (AI) therapy is the most effective hormonal treatment in post-menopausal estrogen receptor (ER) positive breast cancer. These patients may be seen by…
  • Abstract Number: 2199 • 2014 ACR/ARHP Annual Meeting

    Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients

    Bertrand Dunogué1, Magdalena Gerin2, Claire Larroche3, Catherine Montagnier-Petrissans4, Loïc Guillevin5 and Luc Mouthon5, 1Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 2Internal Medicine, Hôpital Jean Verdier, Bondy, France, 3Internal Medicine, Hôpital Avicenne, Bobigny, France, 4Groupe d'Expert AP-HP, Paris, France, 5National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France

    Background/Purpose Intravenous Immunoglobulins (IVIg) have been reported as giving good results in infectious, but also auto-immune related forms of hemophagocytic lymphohistiocytosis (HLH), but only in…
  • Abstract Number: 2200 • 2014 ACR/ARHP Annual Meeting

    Elevated Serum Ferritin Levels in Adult Inpatients As a Predictor of in-Hospital Mortality and Association with Macrophage Activation Syndrome

    Matthew Mullen1, Marcin Trojanowski2, W. Winn Chatham3 and Bita Shakoory3, 1Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Medicine/ Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Macrophage Activation Syndrome (MAS) is a syndrome similar to Familial Hemophagocytic Lymphohistiocytosis (HLH) characterized by increased proliferation and activity of T-cells and macrophages leading…
  • Abstract Number: 2201 • 2014 ACR/ARHP Annual Meeting

    Haematological Complications in Rheumatic Diseases: Not Only Lymphomas

    Elena Elefante1, Chiara Baldini1, Alice Parma1, Elisa Cioffi2, Francesco Ferro1, Roberta Vagelli2, Martina Rousseau3, Rosaria Talarico2, Sara Galimberti3 and Stefano Bombardieri2, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3Hematology Unit, Pisa, Italy

    Background/Purpose Several immunological abnormalities have been reported among patients affected by myelodisplastic syndrome (MDS). On the other hand, a relatively limited number of studies have…
  • Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting

    Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease

    Giulio Cavalli1, Alvise Berti1, Barbara Gulgielmi1, Marco Gelpi2, Riccardo Biavasco2, Corrado Campochiaro1, Alessandro Tomelleri2, Marina Ferrarini3, Maria Grazia Sabbadini2 and Lorenzo Dagna2, 1Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, 2Vita-Salute San Raffaele University, Milan, Italy, 3Department of Oncology, San Raffaele Scientific Institute, MIlan, Italy

    Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…
  • « Previous Page
  • 1
  • …
  • 1903
  • 1904
  • 1905
  • 1906
  • 1907
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology